Is there a relationship between obesity, heart rate variability and inflammatory parameters in heart failure?

Journal of Cardiovascular Medicine

Volumn 11, Issue 2, 2010, Pages 118-124

  Taçoy, Gülten ^a   Açikgöz, Kadri ^a   Kocaman, Sinan Altan ^a   Özdemir, Murat ^a   Çengel, Atiye ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Body mass index; Heart failure; Heart rate variability; Inflammatory parameters

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GLUCOSE;

ADULT; AGED; ARTICLE; BODY MASS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; OBESITY; SMOKING; SYSTOLIC HEART FAILURE;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; HEART FAILURE; HEART RATE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBESITY; PEPTIDE FRAGMENTS;

EID: 75149121059     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328332e730     Document Type: Article

References (44)

1. Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999; 106:605-612.
2. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996-1002.
3. Whilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med 2001; 249:253-261. (Pubitemid 32417788)
4. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305-313.
5. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, et al., CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 2007; 116:627-636.
6. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, Grobbee DE. The prognosis of heart failure in the general population: the Rotterdem Study. Eur Heart J 2001; 22:1318-1327.
7. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001; 38:789-795.
8. Lissin LW, Gauri AJ, Froelicher VF, Ghayoumi A, Myers J, Giacommini J. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. J Cardiac Fail 2002; 8:206-215.
9. Gustafsson F, Kragelund CB, Torp-Pederson C, Seibaek M, Burchardt H, Akkan D, et al., DIAMOND study group. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J 2005; 26:5-7.
10. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, et al. Body mass index and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Cardiac Fail 2003; 9:29-35.
11. Osman AF, Mehra MR, Lavie CJ, Nunez E, Milani RV. The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. J Am Coll Cardiol 2000; 36:2126-2131.
12. Gustaffson F, Torp-Pedersen C, Brendorp B, Seibaek M, Burchardt H, Kober L, DIAMOND Study Group. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J 2003; 24:863-870. (Pubitemid 36528566)
13. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52:1528-1538.
14. Gardner RS, Chong V, Morton I, McDonagh TA. N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-a in patients referred for consideration of cardiac transplantation. Eur J Heart Fail 2005; 7:253-260.
15. Bruins S, Fokkema MR, Romer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, Muskiet FA. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004; 50:2052-2058.
16. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594-600.
17. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43:1590-1595.
18. McCord J, Mundy BJ, Hudson MP, Maisel AS, Hollander JE, Abraham WT, et al., Breathing Not Properly Multinational Study Investigators. Relationship between obesity and B-type natriuretic peptide levels. Ach Intern Med 2004; 164:2247-2252.
19. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO) IV substudy. Circulation 2003; 108:275-281.
20. Camm AJ, Malik M, Bigger JT, Breidhardt G, Cerutti S, Cohen RJ, et al. Task Force of the European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Eur Heart J 1996; 17:354-381. (Pubitemid 26131418)
21. Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, et al. Heartrate turbulence after ventricular premature beats as predictor of mortality after acute myocardial infarction. Lancet 1999; 353:1377-1379.
22. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA, Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. 2002 Recommendations of Doppler echocardiography: a report from the Doppler Quantification Task Force of the nomenclature and Standard Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15:167-184.
23. Pepi M, Tamborini G, Galli C, Barbier P, Doria E, Berti M, et al. A new formula for echo-Doppler estimation of right ventricular systolic pressure. J Am Soc Echocardiogr 1994; 7:20-26.
24. Cicoira M, Maggioni AP, Latini R, Barlera S, Carretta E, Janosi A, et al., on behalf of Val-HeFT Investigators. Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial. Eur J Heart Fail 2007; 9:397-402.
25. Cicoira M, Jankowska E, Doehner W, Zanolla L, Banasiak W, Ponikowski P, et al. Body composition and survival in 511 chronic heart failure patients [abstract]. Eur Heart J 2004; 25:365.
26. Galitzky J, Sengenes C, Thalamas C, Marques MA, Senard JM, LaFontan M, Berlan M. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res 2001; 42:536-544.
27. Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moracca A, Espinosa E, Cola G, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 1997; 15:1695-1699.
28. Messerli FH, Ventura HO, Reisin E, Dreslinski GR, Dunn FG, MacPhee AA, Frohlich ED. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982; 66:55-60.
29. Morabito D, Vallotton MB, Lang U. Obesity is associated with impaired ventricular protein kinase C-MAP kinase signaling and altered ANP mRNA expression in the heart of adult Zucker rats. J Investig Med 2001; 49:310-318.
30. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005; 165:55-61.
31. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al., for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
32. Hasking GL, Esler MD, Jennings LL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73:615-621.
33. Grassi G, Seravelle G, Quarti-Trevano F, Scopelliti F, Dell'Oro R, Bolla G, Mancia G. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension 2007; 49:535-541. (Pubitemid 46263238)
34. Azevedo ER, Kubo T, Mak S, A-Hesayen A, Schofield A, Allan R, et al. Nonselective versus selective b-adrenergic receptor blockade in congestive heart failure. Differential effects on sympathetic activity. Circulation 2001; 104:2194-2199.
35. La Rovere MT, Pinna GD, Maestri R, Robbi E, Caporotondi A, Guazzotti G, et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. JACC 2009; 53:193-200.
36. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003; 361:1077-1083.
37. Anker SD, Coats AJS, Roecker EB, Scherhag A, Packer M. Does carvedilol prevent and reverse cardiac cachexia in patients with severe heart failure? Results of the COPERNICUS study [abstract]. Eur Heart J 2002; 23:394.
38. Abdulla J, Kober L, Abildstrom SZ, Christensen E, James WPT, Torp-Pederson C. Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: a pooled analysis of five registries. Eur Heart J 2008; 29:594-601.
39. Parisch RC, Evans JD. Inflammation in chronic heart failure. Ann Pharmacother 2008; 42:1002-1016.
40. Yndestad A, Dama JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure: the whys and wherefores. Heart Fail Rev 2006; 11:83-92.
41. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi L, Commerford MG, et al., INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640-1649.
42. Stein PK, Barzilay JI, Chaves PH, Traber J, Domitrovich PP, Heckbert SR, Gottdiener JS. Higher levels of inflammation factors and greater insulin resistance are independently associated with higher heart rate and lower heart rate variability in normoglycemic older individuals: the Cardiovascular Health Study. J Am Geriatr Soc 2008; 56:315-321.
43. Ewing DJ, Neilson JM, Shapiro CM, Stewart JA, Reid W. Twenty four hour heart rate variability: effect of posture, sleep and time of day in healthy controls and comparison with bedsite tests of autonomic function in diabetic patients. Br Heart J 1991; 65:239-244.
44. Fauchier L, Babuty D, Melin A, Bonnet P, Cosnay P, Paul Fauchier J. Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail 2004; 6:181-185.